Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™
Kennewick, WA, June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a company pioneering Precision Radionuclide Therapy™ (PRnT) with its innovative RadioGel® technology, today announced the submission of its Early Feasibility IDE application to the FDA. This milestone represents a significant advancement in the Company’s regulatory pathway and builds directly on the substantial progress detailed in its February 10, 2026 update.
Kennewick, WA, June 05, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a company pioneering Precision Radionuclide Therapy™ (PRnT) with its innovative RadioGel® technology, today announced the submission of its Early Feasibility IDE application to the FDA. This milestone represents a significant advancement in the Company’s regulatory pathway and builds directly on the substantial progress detailed in its February 10, 2026 update.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.